Comparison of the effects of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 requiring intubation

Abbas Edalatkhah1, Mohammad Reza Kazemi1*, Fatemeh Samadi Khorshidi2, Zohreh Akhoundimeybodi2, Seyed Mohsen Seyedhosseini3, Soheila Rostami3, Bibi Vaghihe Hosseini3, Zohreh Akhondi3, Yaser Ghelmani4

Received: 25 Jun 2020 Published: 15 Apr 2021

Abstract

Background: Among the medications administered for the management of COVID-19 patients, the induction drugs used for intubation have received little attention. The aim of this study was to compare the effect of induction drugs on the mortality of patients with COVID-19 requiring intubation.

Methods: In this retrospective study, all patients who were admitted to Shahid Sadoughi and Shahid Rahnemoun hospitals in Yazd from February to March 2020 with definitive diagnosis of COVID-19 and needed intubation were enrolled. Patients were divided into 4 groups based on the type of drugs used in intubation, and mortality rate was assessed at the end of the first, second, fourth, and seventh days of the study. Statistical analyses were performed using SPSS 20 and P values <.05 was considered significant.

Results: In this study, 76 patients were examined. Patients were divided into 4 groups, of which 21 were in etomidate group, 8 in ketamine group, 21 in sodium thiopental group, and 35 in midazolam group. Mortality rate in these 4 groups was 25%, 12.5%, 14.3%, and 14.3% (p=0.822), respectively at the end of the first day after intubation; it was 83.3%, 12.5%, 28.6%, and 25.7% (p=0.001), respectively, at the end of the second day; it was 83.3%, 12.5%, 42.9%, and 42.9% (p=0.015), respectively, until the end of the fourth day; it was 100%, 25%, 61.9%, and 65.7% (p=0.007), respectively, until the end of the seventh day. Admission to intubation time interval was 0.91±0.99, 3.12±1.95, 4.09±2.44, and 4.74±2.62 days, respectively (p<0.001).

Conclusion: The results of this study suggest that the use of etomidate may be associated with higher mortality in COVID-19 patients. Further studies are needed to verify the results of this study.

Keywords: Mortality, COVID-19, Intubation, Etomidate

Introduction

Airway management has been one of the biggest challenges in patients with COVID-19 since the beginning of the epidemic. The use of noninvasive methods, such as high-flow nasal cannula and noninvasive ventilation, has been associated with a high risk of transmitting the disease through aerosols despite the fact that a great number of the affected patients require intubation (1). The biggest challenge about the management of the intubation process in

*What is “already known” in this topic:
Induction drugs are one of the essential drugs used for intubation and its selection should be made by considering the complications of the drug and patients’ clinical condition. However, the researchers have given less attention to the drugs used for the intubation of COVID-19 patients.

---What this article adds:
This study revealed that the use of etomidate for intubation of COVID-19 patients can be associated with a higher risk of mortality.

Corresponding author: Dr Mohammad Reza Kazemi, kazemim360@gmail.com

1 Department of Emergency Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran
2 Department of infectious diseases, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 Intensive Care Unit, Nursing Faculty, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4 Clinical Research Development Center of Shahid Sadoughi Hospital. Shahid Sadoughi University of Medical Sciences, Yazd, Iran
these patients has been always the identification of ways to maintain the safety and health of the treatment staff without the slightest interruption in patient treatment. The researchers have given less attention to the induction drugs used for the intubation of COVID-19 patients with regard to their efficacy and complications.

However, patients with COVID-19 are often elderly and have multiple comorbidities, such as hypertension and diabetes (2). The critically ill patients reportedly have a high mortality rate; moreover, 49% to 67% of the patients need to be admitted to intensive care units (3-5), and even up to 97% of them require invasive intubation (6). The most common causes of mortality in COVID-19 patients include respiratory failure (63%), shock (7%), respiratory failure+shock (33%), and unknown causes (7%) (7).

Induction agents constitute an important category of drugs used for intubation. To the best of our knowledge, no previous studies have examined the possible relationship between the drugs used in intubation of COVID-19 patients and their mortality. Thus, the present study aimed to investigate the associations of etomidate, ketamine, sodium thiopental, and midazolam, as induction agents used for intubation, with the in-hospital mortality of COVID-19 patients.

Methods
This retrospective study was conducted on all patients who were admitted to Shahid Sadoughi and Shahid Rahnemoun hospitals in Yazd, Iran, with a definitive diagnosis of COVID-19 and needed intubation from February to March 2020. The definitive diagnosis of the patients had been established based on the reverse transcription-polymerase chain reaction assay.

The demographic and medical information of the patients was collected from medical records by a people who had no role in patient management. The collected demographic information included age, gender, and history of previous illnesses. The recorded medical data were related to the preintubation conditions of patients, including blood pressure, oxygen saturation, heart rate, white blood cell (WBC), and lymphocyte count, BUN, creatinine, sodium (Na), potassium (K), Glasco coma scale (GCS), PH admission to intubation interval, type of drug used for intubation, sequential organ failure assessment (SOFA) score, and the Acute Physiology and Chronic Health Evaluation II (APACHEII) score. The exclusion criteria were (1) information inadequacy; (2) crush intubation; and (3) use of induction drugs other than etomidate, ketamine, sodium thiopental, or midazolam. Finally, the mortality percent was compared among the groups at the end of the first, second, fourth, and seventh days of the study.

Statistical Analysis
All statistical analyses were performed by Statistical Package for Social Sciences (SPSS) software 20th release, using Kruskal Wallis test, One-way ANOVA, and chi square tests. Two tailed P values < .05 was considered significant.

Results
A total of 103 patients were nominated for the study; however, 27 cases were excluded from the study due to information inadequacy (n=8), crush intubation (n=7), and use of drugs other than ketamine, etomidate, sodium thiopental, or midazolam (n=12). Finally, 76 patients were included in the final data analysis, out of whom 47 (61.8%) were male, and the mean age of the patients was 64.39±18.87 (13-94) years (Table 1).

Depending on the type of drug used for induction, the patients were divided into 4 groups of etomida (n=12), ketamine (n=8), sodium thiopental (n=21), and midazolam (n=35). Hypoxia was present in most of the patients (n=58; 76.3%) before intubation. Furthermore, 32 (42.1%) patients had tachycardia with a rate above 100 beats per minute, and 9 (11.8%) had hypotension with a MAP of less than 70 mm Hg.

The results revealed no significant difference among the 4 groups in terms of age, gender distribution, blood pres-

Table 1. Comparison of the age, gender, past medical history and pre-intubation heart rate, mean arterial pressure and oxygen saturation

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Etomidate N=12</th>
<th>Ketamine N=8</th>
<th>Sodium thiopental N=21</th>
<th>Midazolam N=35</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.8±19.8</td>
<td>60.4±23.1</td>
<td>60.3±19.4</td>
<td>68±17.3</td>
<td>0.477*</td>
</tr>
<tr>
<td>Heart rate (beat/min)</td>
<td>103.6±20.9</td>
<td>90.1±14.7</td>
<td>106.1±22.2</td>
<td>94.9±18</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>76.8±9.4</td>
<td>86.3±14.8</td>
<td>87.1±12.6</td>
<td>87.2±18.6</td>
<td>0.094***</td>
</tr>
<tr>
<td>Oxygen Saturation</td>
<td>66.4±13.1</td>
<td>74.25±11.4</td>
<td>76.6±12.3</td>
<td>84.5±12.7</td>
<td>0.224**</td>
</tr>
<tr>
<td>Male gender</td>
<td>7 (58.3%)</td>
<td>7 (87.5%)</td>
<td>11 (52.4%)</td>
<td>22 (62.9%)</td>
<td>0.382***</td>
</tr>
<tr>
<td>Number (percent)</td>
<td>7 (58.3%)</td>
<td>5 (62.5%)</td>
<td>18 (85.7%)</td>
<td>33 (94.3%)</td>
<td>0.014***</td>
</tr>
<tr>
<td>Positive PMH Number (percent)</td>
<td>7 (58.3%)</td>
<td>5 (62.5%)</td>
<td>18 (85.7%)</td>
<td>33 (94.3%)</td>
<td>0.014***</td>
</tr>
<tr>
<td>WBC x10^9/L</td>
<td>7.78±2.42</td>
<td>7.78±2.4</td>
<td>7.83±3.6</td>
<td>6.93±3.35</td>
<td>0.673***</td>
</tr>
<tr>
<td>Lymphocyte count x10^9/L</td>
<td>1.1±0.8</td>
<td>1.4±1.8</td>
<td>1.13±1.1</td>
<td>1.33±1.08</td>
<td>0.497*</td>
</tr>
<tr>
<td>Bun</td>
<td>34.5±25.3</td>
<td>17.12±4.22</td>
<td>21.47±10.95</td>
<td>21.6±12.09</td>
<td>0.448*</td>
</tr>
<tr>
<td>Cr</td>
<td>2.33±2.07</td>
<td>1.10±0.33</td>
<td>1.45±0.91</td>
<td>1.71±1.27</td>
<td>0.333*</td>
</tr>
<tr>
<td>Na</td>
<td>144.5±10.4</td>
<td>135.5±6.45</td>
<td>137.7±6.48</td>
<td>137.0±5.58</td>
<td>0.009**</td>
</tr>
<tr>
<td>K</td>
<td>4.05±0.7</td>
<td>4.61±1.46</td>
<td>3.9±5.8</td>
<td>3.91±0.6</td>
<td>0.155***</td>
</tr>
<tr>
<td>PH</td>
<td>7.37±0.14</td>
<td>7.2±0.16</td>
<td>7.37±0.14</td>
<td>7.3±0.16</td>
<td>0.115*</td>
</tr>
<tr>
<td>GCS</td>
<td>10.66±1.96</td>
<td>10.87±2.1</td>
<td>10.9±1.87</td>
<td>11.3±2.11</td>
<td>0.801*</td>
</tr>
<tr>
<td>Admit to intubation interval (days)</td>
<td>0.91±0.99</td>
<td>3.12±1.95</td>
<td>4.09±2.44</td>
<td>4.74±2.62</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>SOFA score</td>
<td>3.12±2.1</td>
<td>2.8±2.2</td>
<td>3.2±3.18</td>
<td>2.96±2.27</td>
<td>0.116**</td>
</tr>
<tr>
<td>APACHEII score</td>
<td>14.35±5.2</td>
<td>12.41±4.86</td>
<td>14.2±8.04</td>
<td>15.1±5.31</td>
<td>0.097**</td>
</tr>
</tbody>
</table>

*Kruskal Wallis test
**One way Anova
***Chi-square
On this page, the text continues discussing the mortality rates among critically ill patients, with a focus on the use of different medications during intubation. The authors compare four medications: etomidate, ketamine, sodium thiopental, and midazolam, and report statistically significant differences in mortality rates. The data is presented in a table (Table 2) that highlights the number and percentage of patients who survived each day following intubation. The discussion section concludes with a comparison to previous studies and mentions the potential limitations of the study. The page also includes a table with statistical data and a discussion on the implications of these findings.

Table 2: Comparison of mortality rate at the end of the first, second, fourth and seventh days

<table>
<thead>
<tr>
<th>Mortality</th>
<th>Etomidate N=12</th>
<th>Ketamine N=8</th>
<th>Sodium thiopental N=21</th>
<th>Midazolam N=35</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>First day mortality</td>
<td>3 (25%)</td>
<td>1 (12.5%)</td>
<td>3 (14.3%)</td>
<td>5 (14.3%)</td>
<td>0.822</td>
</tr>
<tr>
<td>Second day mortality</td>
<td>10 (83.3%)</td>
<td>1 (12.5%)</td>
<td>6 (28.6%)</td>
<td>9 (25.7%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Fourth day mortality</td>
<td>10 (83.3%)</td>
<td>1 (12.5%)</td>
<td>9 (42.9%)</td>
<td>15 (42.9%)</td>
<td>0.015</td>
</tr>
<tr>
<td>Seven day mortality</td>
<td>12 (100%)</td>
<td>2 (25%)</td>
<td>13 (61.9%)</td>
<td>23 (65.7%)</td>
<td>0.007</td>
</tr>
</tbody>
</table>

*Chi-square

Discussion

The aim of this study was to compare the effect of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 who needed intubation. In our study, patients with direct laryngoscopy or video laryngoscopy were successfully intubated, and none of them were required to use surgical procedures, suggesting that intubation in patients with COVID-19 was not more difficult than other patients. Also, Aziz et al. expressed their experiences gained from the intubation of patients with COVID-19 in Wuhan, China, and reported that 89% of 202 intubated patients admitted to the center at the first try and 100% patients without the need for surgical procedures (8).

However, the recent studies reporting some complications during intubation have caused some considerations in this regard. In a study, the mortality of critically ill patients with COVID-19 was reported to be about 10% in the first 24 hours, and their long-term mortality was 49% (9); however, this rate underwent a remarkable increase after intubation (almost 89%) (3). In the present study, the mortality rates were 15.8%, 34.2%, 46.1%, and 65.8% until the end of the first, second, fourth, and seventh days, respectively.

Before intubation, 76.3%, 42.1%, and 11.8% of our patients had hypoxia, tachycardia, and hypotension, respectively. Similarly, Yao et al (10) reported hypoxia (oxygen saturation of < 90%) and hypotension in 75.2% and 17.8% of patients, respectively, before intubation. In addition, in a study performed by Cheung et al, 73% of the patients suffered from hypoxia, and 80% of them were intubated without non-invasive ventilation that indicated the progressive course of the disease (11).

In the present study, there was no significant difference among the 4 groups in terms of the mortality rate at the end of the first day. However, at the end of the second, fourth, and seventh days, etomidate groups had a significantly higher mortality rate, compared to other groups. In the hospitals investigated in the present study, there was a strong tendency to use sodium thiopental and midazolam, while in the study by Yao et al (10), the most common drugs were propofol (96%), midazolam (13.5%), and etomidate (3%), with several patients being administered with 2 drugs at the same time.

The selection of the medication for patient intubation should be made by considering the complications of the drug and patient clinical condition. Etomidate, a gammahydroxylase and preventing the conversion of cholesterol into cortisol. Therefore, caution should be exercised when using this medication in cases with septic shock and adrenal insufficiency (12).

In 2019, Smischney et al (13) comparing the composition of propofol/ketamine with etomidate for the intubation of 152 critically ill patients, found no significant difference between the 2 groups in terms of the mean changes in blood pressure and the need for vasopressor. In the mentioned study, the etomidate group showed more primary adrenal insufficiency than the other group (81% vs 38%; p=0.027). In addition, the ketamine/propofol group was reported to experience 2 life-threatening complications, while the etomidate group had 4 complications.

The admission to intubation time interval was significantly shorter in the etomidate group. This may show the worse clinical condition in the emergency department or faster deterioration of the patients who had been intubated using etomidate or may be due to the greater interest of the emergency specialists of our medical centers in the use of etomidate.

This study has potential limitations. The effect estimates in the model are based on a retrospective observational study. They are, therefore, subject to biases and confounding that may have influenced our model estimates. Small sample size was another important limitation of this study. Due to the pilot nature of the study and the small sample size, the statistical analyses were not very advanced.
Effect of intubation drugs on the mortality of COVID-19 patients

Conclusion

Based on the results of this study, it can be concluded that the use of etomidate as an induction agent for rapid sequence intubation in patients with COVID-19 can be associated with a higher risk of mortality in these patients. However, the mechanism of this complication is not well understood yet. Further studies are needed to verify the results of this study.

Conflict of Interests

The authors declare that they have no competing interests.

References